Forte Biosciences IncNASDAQ:FBRX
- LAST PRICE7.0900
- TODAY'S CHANGE (%)-0.1700 (-2.3416%)
- Bid / Lots7.0000/ 1
- Ask / Lots7.4500/ 8
- Open / Previous Close7.4500 / 7.2600
- Day Range
- 52 Week Range
- Volume15,519
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBRX |
|---|---|---|
| 09:41 ET | 200 | 7.5 |
| 09:50 ET | 3799 | 7.11 |
| 09:52 ET | 4829 | 7.02 |
| 10:48 ET | 200 | 7.0899 |
| 11:09 ET | 1962 | 7.0899 |
| 11:11 ET | 1400 | 7 |
| 11:13 ET | 600 | 7.09 |
| 01:48 ET | 174 | 6.86 |
| 03:12 ET | 400 | 7.09 |
Aug 19, 2024
DJ Forte Biosciences Is Maintained at Buy by Chardan Capital, from 8:44AM ET on Monday Aug 19, 2024 by Dow Jones
8:44AM ET on Monday Aug 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forte Biosciences Inc | 10.6M | -0.3x | --- |
Check Cap Ltd | 10.6M | -0.6x | --- |
Cell MedX Corp | 10.4M | -17.0x | --- |
GlycoMimetics Inc | 10.5M | -0.3x | --- |
Kiora Pharmaceuticals Inc | 10.1M | -0.5x | --- |
Mustang Bio Inc | 9.7M | -0.1x | --- |
Company Information
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Contact Information
- Headquarters
- 3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
- Phone
- 310-618-6994
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Wagner
- Chief Financial Officer
- Antony Riley
- Independent Director
- Scott Brun
- Independent Director
- Stephen Doberstein
- Independent Director
- Lawrence Eichenfield
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.02 |
EPS | $-22.03 |
Book Value | $24.30 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
